Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Avi I. Einzig"'
Autor:
Avi I. Einzig, Chandra P. Belani, T. Dobbs, Slawomir Wojtowicz-Praga, P. Bonomi, Sakkaraiappan Ramalingam, Marianne Cascino
Publikováno v:
Cancer Chemotherapy and Pharmacology. 53:439-444
To evaluate the efficacy of carboplatin and docetaxel combination in patients with advanced non-small-cell lung cancer. In a phase II study, patients with inoperable stage IIIB or stage IV non-small-cell lung cancer (ECOG performance status of 0 or 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae213a48edd910943e810c03e6e62801
https://doi.org/10.1007/s00280-003-0752-3
https://doi.org/10.1007/s00280-003-0752-3
Publikováno v:
The Cancer Journal. 8:282-286
PURPOSE The Eastern Cooperative Oncology Group conducted a randomized phase II trial to determine the objective response rates, toxicities, and overall survival and to assess effects on quality of life for two combination regimens in patients with ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7490a2981641970aab672a11904c7d1d
https://doi.org/10.1097/00130404-200205000-00013
https://doi.org/10.1097/00130404-200205000-00013
Publikováno v:
American Journal of Hematology. 84:455-457
Despite major advances in the treatment of acute myeloid leukemia (AML) in adults over the last 3 decades, most patients with other than acute promyelocytic leukemia (APL) still succumb to the disease. For young adults (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96ff1ec3366f828271de49b6f99a928c
https://doi.org/10.1002/ajh.21431
https://doi.org/10.1002/ajh.21431
Autor:
Sylvia Thomas, Williamn R. Grove, Laura Benson, Chetan D. Lathia, Nancy T. Sklarin, Avi I. Einzig, Javier Roca, Peter H. Wiernik
Publikováno v:
Investigational New Drugs. 15:235-246
CI-980 is a synthetic mitotic inhibitor that binds to the colchicine binding site of tubulin. It demonstrates broad activity against human and murine tumor models and shows no cross resistance with tumor models whose mechanism of resistance is mediat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::160ac4c6bb3bf5e831456b18370cecb8
https://doi.org/10.1023/a:1005854510468
https://doi.org/10.1023/a:1005854510468
Autor:
Avi I. Einzig, Susan Band Horwitz, Yuexian Wang, Kevin P. O'Boyle, Janice P. Dutcher, Edward L. Schwartz, Donna Lee Regl, Peter H. Wiernik
Publikováno v:
Cancer. 79:1022-1030
BACKGROUND Paclitaxel is an antimitotic agent isolated from the Pacific yew tree. It has demonstrated antitumor activity in several cancers and is the first of a new class of antineoplastic agents containing a taxane ring system. Its levels in serum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d77d76a132d02aaf3b02359284b761e
https://doi.org/10.1002/(sici)1097-0142(19970301)79:5<1022::aid-cncr20>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19970301)79:5<1022::aid-cncr20>3.0.co
Autor:
Peter H. Wiernik, Peter J. O'Dwyer, Nicholas J. Petrelli, Donna Neuberg, Guillermo Ramirez, Avi I. Einzig, Louise B. Grochow
Publikováno v:
American Journal of Therapeutics. 3:750-754
Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m(2) in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxity and 15 were assessable for response. There were no com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::713c6ac0e59329f7b7f14a0ddc28b923
https://doi.org/10.1097/00045391-199611000-00003
https://doi.org/10.1097/00045391-199611000-00003
Autor:
Avi I. Einzig, Susan Coatsworth, Adri Recio, Peter H. Wiernik, Lynn M. Schuchter, Roberto Rodriquez
Publikováno v:
Medical Oncology. 13:111-117
A phase II study was undertaken to evaluate the clinical efficacy and safety of docetaxel in patients with malignant melanoma. Between April 1992 and February 1996, 37 patients with metastatic malignant melanoma and no prior chemotherapy were treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21207a61c6b3bc4f6fc52b581f678405
https://doi.org/10.1007/bf02993861
https://doi.org/10.1007/bf02993861
Publikováno v:
Investigational New Drugs. 13:223-227
Taxol was administered as a 24-hour continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered between July 1991 and June 1992, twenty-three w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d9fb1fe8b4ba443ab37626df35cd467
https://doi.org/10.1007/bf00873804
https://doi.org/10.1007/bf00873804
Autor:
Avi I. Einzig, E. L. Schwartz, Peter H. Wiernik, Scott Wadler, Zhihang Lu, R. B. Diasio, Ruiwen Zhang, Joseph A. Sparano
Publikováno v:
Journal of Clinical Oncology. 11:1609-1617
PURPOSE To determine the maximum-tolerable dose (MTD) of fluorouracil (5-FU) administered as a low-dose, prolonged continuous intravenous infusion (PCI) plus interferon-alfa (IFN-alpha) that would permit treatment for at least 28 consecutive days, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::836397fcdec86894f416d24c786a96e0
https://doi.org/10.1200/jco.1993.11.8.1609
https://doi.org/10.1200/jco.1993.11.8.1609
Publikováno v:
Cancer. 71:1591-1596
Taxol is a structurally complex natural plant product with a novel mechanism of action. The supply of this drug is limited by its low abundance in the bark of the slow-growing yew tree from which it is extracted. The chemical complexity of taxol has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0fa2208ec28cf95bfd88709e1fda4125
https://doi.org/10.1002/cncr.2820710442
https://doi.org/10.1002/cncr.2820710442